Skip to main content
Top
Published in: Supportive Care in Cancer 6/2016

01-06-2016 | Original Article

The impact of chemotherapy for breast cancer on sexual function and health-related quality of life

Authors: Juliane Farthmann, A. Hanjalic-Beck, J. Veit, B. Rautenberg, E. Stickeler, T. Erbes, M. Földi, A. Hasenburg

Published in: Supportive Care in Cancer | Issue 6/2016

Login to get access

Abstract

Purpose

In this prospective trial, we evaluated the influence of chemotherapy for breast cancer on women’s health-related quality of life (HR-QoL), sexual function, and mental status.

Methods

The patients completed validated questionnaires on HR-QoL, sexual function, and depression before, during, and at the end and finally 6 months after chemotherapy. Special attention was paid to possible differences between pre- and postmenopausal patients.

Results

Between 2008 and 2012, 79 patients were enrolled in the trial (mean age 47.46 years). Premenopausal participants were 63.3 %. Sexual activity dropped from 71.9 % before chemotherapy to a minimum of 47 % at the end of chemotherapy. A similar effect was seen for pleasure and discomfort. Depression values were the highest at the beginning of chemotherapy, with spontaneous improvement in many patients during the course of time. HR-QoL and global health status both increased 6 months after therapy. For almost all parameters, changes were more obvious in pre- than in postmenopausal patients.

Conclusions

In a close monitoring, we observed significant changes in HR-QoL, depression, and sexual function in breast cancer patients. Special attention needs to be paid to premenopausal patients. The knowledge of effective recovery and spontaneous improvement of HR-QoL in spite of still impaired sexuality are important information in counseling both pre- and postmenopausal patients with diagnosis of breast cancer prior to upcoming therapy.
Literature
1.
go back to reference Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1271CrossRefPubMed Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E (2002) Twenty-year follow up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227–1271CrossRefPubMed
5.
go back to reference Perz J, Ussher J, Gilbert E (2013) Loss, uncertainty, or acceptance: subjective experience of changes to fertility after breast cancer. Eur J Cancer Care (Engl). doi:10.1111/ecc.12165 Perz J, Ussher J, Gilbert E (2013) Loss, uncertainty, or acceptance: subjective experience of changes to fertility after breast cancer. Eur J Cancer Care (Engl). doi:10.​1111/​ecc.​12165
7.
9.
go back to reference Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol 16(3):1188–1196PubMed Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol 16(3):1188–1196PubMed
10.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al. (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 3;85(5):365–376. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al. (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 3;85(5):365–376.
11.
go back to reference Fayers PM, Aaronson NK, Bjordal K, et al., on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual (3rd edition). European Organisation for Research and Treatment of Cancer, Brussels. Fayers PM, Aaronson NK, Bjordal K, et al., on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 Scoring Manual (3rd edition). European Organisation for Research and Treatment of Cancer, Brussels.
12.
go back to reference Thirlaway K, Fallowfield L, Cuzick J (1996) The Sexual Activity Questionnaire: a measure of women’s sexual functioning. Qual Life Res 5(1):81–90 Erratum in: Qual Life Res 1997 Aug;6(6):606CrossRefPubMed Thirlaway K, Fallowfield L, Cuzick J (1996) The Sexual Activity Questionnaire: a measure of women’s sexual functioning. Qual Life Res 5(1):81–90 Erratum in: Qual Life Res 1997 Aug;6(6):606CrossRefPubMed
13.
go back to reference Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino Jr R (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208CrossRefPubMed Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino Jr R (2000) The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 26(2):191–208CrossRefPubMed
14.
go back to reference Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N (2005) Quality of life in long-term cervical cancer survivors. Gynecol Oncol 97(2):310–317CrossRefPubMed Wenzel L, DeAlba I, Habbal R, Kluhsman BC, Fairclough D, Krebs LU, Anton-Culver H, Berkowitz R, Aziz N (2005) Quality of life in long-term cervical cancer survivors. Gynecol Oncol 97(2):310–317CrossRefPubMed
15.
go back to reference Hautzinger M, Bailer M (1993) Allgemeine Depressions Skala. Manual. Göttingen, Beltz Test GmbH Hautzinger M, Bailer M (1993) Allgemeine Depressions Skala. Manual. Göttingen, Beltz Test GmbH
16.
go back to reference Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement. 1:385–401CrossRef Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement. 1:385–401CrossRef
17.
go back to reference Jankowska M (2013) Sexual functioning in young women in the context of breast cancer treatment. Rep Pract Oncol Radiother 18(4):193–200 eCollection 2013CrossRefPubMedPubMedCentral Jankowska M (2013) Sexual functioning in young women in the context of breast cancer treatment. Rep Pract Oncol Radiother 18(4):193–200 eCollection 2013CrossRefPubMedPubMedCentral
18.
go back to reference Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 223(8):2215–2224. doi:10.1007/s00520-014-2571-y CrossRef Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M (2015) Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer 223(8):2215–2224. doi:10.​1007/​s00520-014-2571-y CrossRef
19.
go back to reference Callari A, Mauri M, Miniati M, Mancino M, Bracci G, Dell'osso L, Greco C (2013) Treatment of depression in patients with breast cancer: a critical review. Tumori 99(5):623–633. doi:10.1700/1377.15313 PubMed Callari A, Mauri M, Miniati M, Mancino M, Bracci G, Dell'osso L, Greco C (2013) Treatment of depression in patients with breast cancer: a critical review. Tumori 99(5):623–633. doi:10.​1700/​1377.​15313 PubMed
Metadata
Title
The impact of chemotherapy for breast cancer on sexual function and health-related quality of life
Authors
Juliane Farthmann
A. Hanjalic-Beck
J. Veit
B. Rautenberg
E. Stickeler
T. Erbes
M. Földi
A. Hasenburg
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-3073-2

Other articles of this Issue 6/2016

Supportive Care in Cancer 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine